Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab



Status:Completed
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:18 - 80
Updated:1/13/2019
Start Date:October 10, 2016
End Date:August 13, 2018

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects With Moderate to Severe Rheumatoid Arthritis

This trial is designed to determine what effects the human body has on the investigational
medicine, ABP 710, and what effects the body has on the investigational medicine after you
have been given it, and if this is comparable to what is seen for the licensed medicine,
infliximab, in patients with moderate or severe rheumatoid arthritis (RA).

This study will assess if the investigational medicine is safe and effective in

treating moderate or severe RA compared to the licensed medicine.


Inclusion Criteria:

- Subject (man or woman) is ≥ 18 and ≤ 80 years old.

- Subject is diagnosed with RA as determined by meeting the the 2010 American College of
Rheumatology (ACR)/European League Against Rheumatism classification criteria for RA.

- Subject has RA duration of at least 3 months.

- Subject has active RA defined as ≥ 6 swollen joints and ≥ 6 tender joints (based on
66/68 joint count excluding distal interphalangeal joints) at screening and baseline
and at least 1 of the following at screening:

- erythrocyte sedimentation rate ≥ 28 mm/hr

- serum C-reactive protein > 1.0 mg/dL

- Subject has a positive rheumatoid factor or anti-cyclic citrullinated peptide at
screening.

- Subject has taken MTX for ≥ 12 consecutive weeks and is on a stable dose of oral or
subcutaneous MTX 7.5 to 25 mg/week for ≥ 8 weeks before receiving the investigational
product and is willing to remain on a stable dose throughout the study.

- For a subject on nonsteroidal anti-inflammatory drugs or low potency analgesics such
as tramadol, Soma Compounds, Fioricet, or Fiorinal, the dose should be stable for ≥ 2
weeks before screening.

- For a subject on oral corticosteroids (≤ 10 mg prednisone or equivalent), the dose
should be stable for ≥ 4 weeks before screening.

- Subject has no known history of active tuberculosis.

- Subject has a negative test for tuberculosis during screening defined as either:

- negative purified protein derivative (PPD) defined as < 5 mm of induration at 48
to 72 hours after test is placed

OR

- negative Quantiferon test

- Subject with a positive PPD and a history of Bacillus Calmette-Guérin vaccination
is allowed with a negative Quantiferon test.

- Subject with a positive PPD test (without a history of Bacillus Calmette-Guérin
vaccination) or a subject with a positive or indeterminate Quantiferon test is
allowed if they have all of the following:

- no symptoms of tuberculosis according to the worksheet provided by the sponsor, Amgen
Inc.

- documented history of adequate prophylaxis initiation before receiving investigational
product in accordance with local recommendations

- no known exposure to a case of active tuberculosis after most recent prophylaxis

Exclusion Criteria:

- Subject has a history of prosthetic or native joint infection.

- Subject has an active infection or history of infections as follows:

- any active infection for which systemic anti-infectives were used within 28 days
before first dose of investigational product

- a serious infection, defined as requiring hospitalization or intravenous (IV)
anti-infective(s) within 8 weeks before the first dose of investigational product

- recurrent or chronic infections or other active infection that, in the opinion of the
investigator, might cause this study to be detrimental to the subject

- Subject has a positive blood test for human immunodeficiency virus.

- Subject has a positive hepatitis B surface antigen, hepatitis B core antibody, or
hepatitis C virus antibody result at screening.

- Subject has uncontrolled, clinically significant systemic disease such as diabetes
mellitus, cardiovascular disease including moderate or severe heart failure (New York
Heart Association Class III/IV), renal disease, liver disease, or hypertension.

- Subject had a malignancy within 5 years EXCEPT for treated and considered cured
cutaneous squamous or basal cell carcinoma, in situ cervical cancer, OR in situ breast
ductal carcinoma.

- Subject has a history of neurologic symptoms suggestive of central or peripheral
nervous system demyelinating disease.

- Subject has a major chronic inflammatory disease or connective tissue disease other
than RA, with the exception of secondary Sjögren's syndrome.

- Subject has a concurrent medical condition that, in the opinion of the investigator,
could cause this study to be detrimental to the subject.

- Subject has laboratory abnormalities at screening, including any of

the following:

- hemoglobin < 9 g/dL

- platelet count < 100 000/mm3

- white blood cell count < 3 000/mm3

- aspartate aminotransferase and/or alanine aminotransferase ≥ 2.0 x the upper limit of
normal

- creatinine clearance < 50 mL/min (Cockroft-Gault formula)

- any other laboratory abnormality, that, in the opinion of the investigator, will
prevent the subject from completing the study or will interfere with the
interpretation of the study results.

- Subject has used commercially available or investigational biologic therapies for
RA as follows:

- anakinra, etanercept within 1 month before the first dose of investigational product

- abatacept, tocilizumab, adalimumab, golimumab, certolizumab within 3 months before the
first dose of investigational product

- other experimental or commercially available biologic therapies for RA within 3 months
or 5 half-lives (whichever is longer) before the first dose of investigational product

- rituximab within 9 months before the investigational product along with evidence of
incomplete B cell recovery

- Subject has received live vaccines within 28 days before the first dose of
investigational product or plans to receive live vaccines during the course of
the study.

- Subject has previously received Remicade® (infliximab) or a biosimilar of
infliximab.

- Woman who is pregnant or breast feeding, or plans to become pregnant while
enrolled in the study and for 6 months after the last dose of investigational
product.

- Woman who is of childbearing potential (ie, neither surgically sterile nor
postmenopausal) and does not agree to use adequate contraception (eg, true
abstinence, sterilization, birth control pills, Depo-Provera®
[medroxyprogesterone] injections, or contraceptive implants) while on study and
for 6 months after the last dose of investigational product.
We found this trial at
27
sites
?
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
?
mi
from
Aventura, FL
Click here to add this to my saved trials
?
mi
from
Carrollton, TX
Click here to add this to my saved trials
Charleston, South Carolina 29412
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charlotte, North Carolina 28207
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
?
mi
from
Covina, CA
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Flowood, MS
Click here to add this to my saved trials
?
mi
from
Grand Blanc, MI
Click here to add this to my saved trials
?
mi
from
Hemet, CA
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Huntsville, AL
Click here to add this to my saved trials
?
mi
from
League City, TX
Click here to add this to my saved trials
?
mi
from
Lexington, KY
Click here to add this to my saved trials
?
mi
from
Memphis, TN
Click here to add this to my saved trials
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Orlando, FL
Click here to add this to my saved trials
?
mi
from
Peoria, AZ
Click here to add this to my saved trials
?
mi
from
Plano, TX
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
?
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
?
mi
from
Upland, CA
Click here to add this to my saved trials
?
mi
from
Van Nuys, CA
Click here to add this to my saved trials
?
mi
from
Vero Beach, FL
Click here to add this to my saved trials
?
mi
from
Voorhees, NJ
Click here to add this to my saved trials
?
mi
from
Woodville,
Click here to add this to my saved trials